Biosimilar Manufacturing solution center

41. Accelerating Autologous CAR T Cell Expansion With Automation 6/19/2026

    Scaling CAR T manufacturing demands high expansion without exhaustion. Examine integrated, semi-automated approaches with digital traceability that can improve consistency and preserve cell function.

42. Evaluating CAR T Cell Therapy Processing 6/19/2026

    Serum-free media is reshaping CAR T manufacturing. Gain insight into how media-agnostic platforms offer the flexibility to adapt workflows without re-optimization, helping teams streamline processes.

43. The Scale-Up Of A Transient rAAV8 Production Process 6/18/2026

    New approaches to suspension cell culture and process scaling enable consistent, high-titer rAAV production. Gain insight into a clearer path to scalable manufacturing for gene therapy pipelines.

44. Unlocking The Full Potential Of Antibody-Drug Conjugates (ADCs) 6/15/2026

    ADCs are evolving rapidly. Gain insight into how success now hinges on managing complexity, delivery, and scalability to turn promising designs into viable therapeutic products.

45. ADC Manufacturing: Practices, Challenges, And The Road Ahead 6/15/2026

    ADCs are advancing quickly, but manufacturing complexity is rising just as fast. Key challenges in scale-up, regulation, and costs are reshaping how the next generation of therapies will be delivered.

46. Scalable rAAV9 Production Using Advanced Cell Lines And Bioreactors 6/15/2026

    Progress in gene therapy manufacturing is being driven by improved cell line performance and scalable bioprocessing. See how high-density growth helps streamline development to larger-scale production.

47. Where Does 3D-Printed Single-Use Tech Fit In The Development Pipeline? 6/10/2026

    Additive manufacturing in early-phase process development is growing more common, but the practice comes with important considerations.

48. A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis 6/5/2026

    This is the first published application of data envelopment analysis to six major pharmaceutical analytical validation guidelines, including ICH Q2(R2), USP, ChP, and Brazil's ANVISA.

49. Affinity Membranes Are Moving Closer To Commercial Reality 6/5/2026

    A recent review shows advances in surface chemistry and ligand engineering are moving the needle for next-generation affinity membranes.

50. AI Has Arrived In Biotech CMC Amid Patchwork Governance 6/3/2026

    AI is surfacing within regulatory and CMC workflows at a vigorous pace. Unfortunately, in small and midsize biotechs, it's happening faster than governance can keep up.